The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
The company will manufacture a cancer immunotherapy product from 2022
The platform’s technology works as a compression algorithm for molecular testing
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The state-of-the-art facility provides a pathway from development to large-scale biologics production
The company does not expect the outcome of this inspection to impact its plans
Subscribe To Our Newsletter & Stay Updated
